Home » HHS Override of FDA’s Plan B Review Could Signal Precedent, Hurts FDA’s Predictability Push
HHS Override of FDA’s Plan B Review Could Signal Precedent, Hurts FDA’s Predictability Push
HHS Secretary Kathleen Sebelius’ decision to override a favorable review by CDER on OTC sales of Teva’s Plan B contraceptive could be a precedent-setting move that has put the FDA in uncomfortable political crosshairs amid its push to improve regulatory science and predictability.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May